{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Table 9:', 'Prohibited Medications Associated with CYP3A4 Induction or Inhibition', '(Continued)', 'Generic Name', 'Brand Name', 'rifampin', 'Rifidin, Rimactane', 'rifapentine', 'Priftin', 'ritonavir', 'Norvir', 'saquinavir', 'Invirase, Fortovase', 'telaprevir', 'Incivek', 'telithromycin', 'Ketek', 'tofisopam', 'Emandaxin, Grandaxin', 'Table 10:', 'Prohibited Food and Herbal Supplements Associated with CYP3A4', 'Induction or Inhibition', 'Name', 'Brand Names', 'Notes/Description', 'Grapefruit/Grapefruit juice', 'Includes sodas that contain', 'concentrated grapefruit juice', 'Marmalade', 'Seville/blood oranges', \"St. John's Wort\", 'Curcumin', '78', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.11.', 'Appendix 11: Guidance to Address a Pandemic or Other Global', 'Health Emergencies and Potential Impact on the Clinical Study', 'In the occurrence of a global health pandemic affecting the conduct of the ongoing study, such as', 'the COVID-19 pandemic, study conduct may be adjusted due to subjects being in self-', 'isolation/quarantine, limited access to public places (including hospitals) due to the risk of', 'spreading infections, and health care professionals being committed to critical tasks (FDA, 2020;', 'EMA, 2020; Health Canada, 2020; MHRA, 2020).', 'Adjustments to the GB001-2101 protocol may be made as described below, in line with global', 'regulatory authorities guidance in order to ensure the safety of study participants, maintain', 'compliance with GCP, and minimize the risks to trial integrity during the COVID-19 pandemic', '(FDA, 2020; EMA, 2020; Health Canada, 2020; MHRA, 2020). Member states within the', 'National Competent Authorities may issue their own guidance requiring country specific', 'recommendations to be followed.', 'In the case of missed visits due to COVID-19 (or other health pandemic) related', 'reasons:', '- The site should make every effort to contact the subject to confirm and document', 'the reason for the missed visit, and at minimum evaluate AEs/SAEs, concomitant', 'medications, and the SNOT-22 questionnaire in order to assess subject status.', '-', 'The subject should continue to collect the daily morning and evening symptom', 'diary as described in Section 8.1.4.', 'Alternative methods of collecting study assessments may be considered where', 'possible:', '- Questionnaires, including SNOT-22, UPSIT, and ACQ-5, may be self-', 'administered by the subject at home.', '-', 'In certain situations, with Sponsor approval, a local laboratory may be used.', 'Alternative methods of supplying IP to study subjects (eg, direct-to-patient shipment', 'from site) may be considered where possible.', '-', 'With prior sponsor approval, IP may be supplied via alternative methods provided', 'that laboratory assessments are able to be performed prior to the delivery of IP. In', 'all cases, study subjects must provide consent for alternative delivery methods.', \"Documentation of consent will be captured in the subject's study records.\", '79', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.12.', 'Appendix 12: Abbreviations', 'Abbreviation Term', 'Description', 'ACQ-5', 'Asthma Control Questionnaire', 'AE', 'adverse event', 'AERD', 'aspirin-exacerbated respiratory disease', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase', 'ANCOVA', 'analysis of covariance', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the curve', 'BID', 'twice daily', 'BMI', 'body mass index', 'BUN', 'blood urea nitrogen', 'CI', 'confidence interval', 'CIOMS', 'Council for International Organizations of Medical Sciences', 'CONSORT', 'Consolidated Standards of Reporting Trials', 'COX-2', 'cyclooxygenase 2', 'CRS', 'chronic rhinosinusitis', 'CRSsNP', 'chronic rhinosinusitis without nasal polyps', 'CRSwNP', 'chronic rhinosinusitis with nasal polyps', 'CSR', 'clinical study report', 'CT', 'Computed Tomography', 'CTFG', 'Clinical Trial Facilitation Group', 'CysLT', 'cysteinyl leukotriene', 'DILI', 'drug induced liver injury', 'DP2', 'prostaglandin D2 receptor', 'ECG', 'electrocardiogram', 'ECP', 'eosinophil cationic protein', 'eCRF', 'electronic case report form', 'eCRS', 'eosinophilic chronic rhinosinusitis', 'EW', 'early withdrawal', 'FeNO', 'fractional exhaled nitric oxide', 'FEV1', 'forced expiratory volume in 1 second', '80', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}